Published 2 years ago • loading... • Updated 2 years ago

Therapeutic-dose anticoagulation may improve COVID-19 outcomes for noncritical inpatients – Healio

Summary by Ground News

A therapeutic vs. prophylactic dose of anticoagulation therapy did not significantly improve outcomes for noncritically ill patients hospitalized with COVID-19. The FREEDOM COVID trial ultimately did not meet its primary endpoint, Valentin Fuster, MD, PhD, said during a late-breaking clinical trials presentation.

2 Articles

All

Left

Center

Right

Healio

Center

Therapeutic-dose anticoagulation may improve COVID-19 outcomes for noncritical inpatients

NEW ORLEANS — A therapeutic vs. prophylactic dose of anticoagulation therapy did not significantly improve outcomes for noncritically ill patients hospitalized with COVID-19, though fewer therapeutic dose-treated patients died at 30 days.The FREEDOM COVID trial ultimately did not meet its primary endpoint — a 30-day composite of all-cause mortality, ICU admission, systemic

2 years ago

Read Full Article